Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BIRC2 | Q13490 | 12/20 | 0.42 |
| ▸ | XIAP | P98170 | 12/20 | 0.42 |
| ▸ | BIRC3 | Q13489 | 7/20 | 0.42 |
| ▸ | CASP9 | P55211 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | TNF | P01375 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9613412 | 1.00 | BIRC2 (0.42) | BIRC2XIAPBIRC3CASP9CYP3A4 | |
| SCHEMBL9613410 | 0.95 | BIRC2 (0.43) | BIRC2XIAPBIRC3CASP9CYP3A4 | |
| SCHEMBL8513783 | 0.95 | BIRC2 (0.43) | BIRC2XIAPBIRC3CASP9CYP3A4 | |
| SCHEMBL13017986 | 0.92 | BIRC2 (0.42) | BIRC2XIAPBIRC3CASP9CYP3A4 | |
| SCHEMBL8510536 | 0.92 | XIAP (0.44) | BIRC2XIAPBIRC3CASP9CYP3A4 | |
| SCHEMBL9613411 | 0.92 | BIRC2 (0.42) | BIRC2XIAPBIRC3CASP9CYP3A4 | |
| SCHEMBL8514515 | 0.92 | BIRC2 (0.42) | BIRC2XIAPBIRC3CASP9CYP3A4 | |
| SCHEMBL9613512 | 0.92 | XIAP (0.44) | BIRC2XIAPBIRC3CASP9CYP3A4 | |
| SCHEMBL8511131 | 0.91 | BIRC2 (0.42) | BIRC2XIAPBIRC3CASP9CYP3A4 | |
| SCHEMBL8511128 | 0.91 | BIRC2 (0.42) | BIRC2XIAPBIRC3CASP9CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8415486-B2 | IAP inhibitors | TETRALOGIC PHARMACEUTICALS CORP. (US) | 2013-04-09 | — | — | US | disclosed |
| US-20120135990-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUTICALS CORP. (US) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135990-A1 | IAP INHIBITORS | XIAP, IAPP, BIRC5 | BIRC2 4/4885XIAP 1/4885BIRC3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.